MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-14-2024
T2 Biosystems Net Income 2011-2025 | TTOO
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income T2 Biosystems
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -50.1 M | -62 M | -49.2 M | -46.8 M | -59 M | -51.2 M | -62.4 M | -54.8 M | -45.3 M | -31.4 M | -20.6 M | -14.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -14.5 M | -62.4 M | -45.6 M |
Quarterly Net Income T2 Biosystems
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -10.1 M | -8.96 M | -13.5 M | - | -15.4 M | -6.35 M | -18 M | - | -17.4 M | -18 M | -16.5 M | - | -14 M | -12.5 M | -10.7 M | - | -11.3 M | -10.7 M | -14.9 M | -14 M | -14.2 M | -15.6 M | -15.1 M | -15.1 M | -10.8 M | -12.3 M | -12.9 M | -18.2 M | -14.1 M | -15.5 M | -14.7 M | -14.5 M | -12.8 M | -14 M | -13.4 M | -12 M | -11.6 M | -11 M | -10.6 M | -9.08 M | -8.09 M | -7.3 M | -6.92 M | -6.37 M | -4.64 M | -5.01 M | -4.58 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -4.58 M | -18.2 M | -12.2 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brainsway Ltd.
BWAY
|
-6.46 M | $ 19.29 | -1.73 % | $ 99.4 M |  Israel |
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
DarioHealth Corp.
DRIO
|
-59.4 M | $ 10.04 | -0.99 % | $ 285 M | Israel |
 |
DexCom
DXCM
|
542 M | $ 67.42 | 0.84 % | $ 26 B |  USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
-865 M | $ 101.54 | -0.05 % | $ 18.8 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 21.26 | -2.34 % | $ 229 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-112 M | $ 1.52 | -0.65 % | $ 1.93 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 40.09 | -0.27 % | $ 1.11 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
3.9 B | $ 231.47 | 0.28 % | $ 169 B | USA |
 |
NeoGenomics
NEO
|
-78.7 M | $ 12.3 | -0.97 % | $ 1.56 B | USA |
 |
Neogen Corporation
NEOG
|
-1.09 B | $ 7.14 | -0.14 % | $ 1.55 B | USA |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 27.01 | -0.55 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
OPKO Health
OPK
|
14 M | $ 1.3 | -0.76 % | $ 902 M | USA |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Pacific Biosciences of California
PACB
|
-307 M | $ 1.88 | 3.3 % | $ 477 M | USA |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 26.98 | 0.37 % | $ 20 B |  Niderland |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
Precipio
PRPO
|
-5.85 M | $ 23.89 | 2.56 % | $ 31 M | USA |
 |
CareDx, Inc
CDNA
|
-190 M | $ 19.73 | -1.45 % | $ 1.06 B | USA |
 |
Celcuity
CELC
|
-112 M | $ 102.61 | 0.25 % | $ 4.05 B | USA |
 |
QIAGEN N.V.
QGEN
|
83.6 M | $ 45.48 | -0.29 % | $ 10.1 B | Niderland |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Anixa Biosciences
ANIX
|
-12.6 M | $ 3.42 | 3.64 % | $ 109 K | USA |
 |
Co-Diagnostics
CODX
|
-35.3 M | $ 0.24 | -1.79 % | $ 7.04 M | USA |
 |
IQVIA Holdings
IQV
|
1.37 B | $ 226.02 | 0.39 % | $ 41 B | USA |
 |
Sotera Health Company
SHC
|
44.4 M | $ 17.7 | 1.67 % | $ 5.01 B | USA |
 |
Guardant Health
GH
|
-436 M | $ 102.38 | -0.12 % | $ 12.6 B | USA |
 |
Soleno Therapeutics
SLNO
|
-176 M | $ 49.14 | 0.61 % | $ 1.97 B | USA |
 |
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
Trinity Biotech plc
TRIB
|
929 K | $ 1.02 | -20.31 % | $ 61.9 M |  Irlanda |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Twist Bioscience Corporation
TWST
|
-77.7 M | $ 33.58 | -0.77 % | $ 2.01 B | USA |
 |
Mettler-Toledo International
MTD
|
863 M | $ 1 417.16 | 0.18 % | $ 30.1 B |  Schweiz |
 |
Illumina
ILMN
|
-1.22 B | $ 135.32 | -0.64 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
22.2 M | $ 203.16 | 0.14 % | $ 10.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-11.5 M | $ 5.1 | - | $ 2.74 M | USA |
 |
Quotient Limited
QTNT
|
-111 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Quest Diagnostics Incorporated
DGX
|
871 M | $ 175.92 | 0.48 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
-42.9 M | $ 6.82 | 1.04 % | $ 884 M | USA |
 |
Myriad Genetics
MYGN
|
-127 M | $ 6.55 | -0.15 % | $ 593 M | USA |